There is a lack of comparative effectiveness research, particularly in the clinical setting, guiding psoriasis therapy.
Objective
To compare the efficacies of the traditional systemic, biologic, and combination therapies.
Methods
This retrospective cohort study analyzed psoriasis patient visits to the Tufts Medical Center Department of Dermatology. The outcome measure used was the validated simple measure for assessing psoriasis activity (S-MAPA).
Results
Patients treated with biologic or combination therapies had a significantly larger improvement in S-MAPA than patients treated with a traditional systemic medication at 24 weeks (biologic: 62.69% vs. 36.20%, p=0.021; combination: 83.28% vs. 36.20%, p=0.011). Multivariate analysis demonstrated the superiority of biologics to traditional systemic therapy was independent of patient demographics and comorbidities.
Conclusions
In the clinical setting, the biologic and combination therapies are superior to the traditional systemic therapies in the treatment of psoriasis. Emphasis should be placed on future trials that compare current active therapies.
ParisiR.SymmonsD.P.M.GriffthsC.E.M.AshcroftD.M.. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence.J Invest Dermatol. Feb 2013; 133(2): 377–285.
2.
GriffithsC.E.BarkerJ.N.. Pathogenesis and clinical features of psoriasis. Lancet.Jul 212007; 370(9583): 263–271.
3.
HerrierR.N.. Advances in the treatment of mode rate-to-severe plague psoriasis. Am J Health Syst Pharm.May 12011; 68(9): 795–806.
4.
NaldiL.SvenssonA.DiepgenT.Randomized clinical trials for psoriasis 1977–2000: the EDEN survey.J Invest Dermatol. May 2003; 120(5): 738–741.
5.
NaldiL.SvenssonA.ZenoniD.Comparators, study duration, outcome measures and sponsorship in therapeutic trials of psoriasis: update of the EDEN Psoriasis Survey 2001–2006. Br J Dermatol.Feb 12010; 162(2): 384–389.
6.
StaffordR.S.WagnerT.H.LavonP.W.. New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. N Engl J Med.Sep 242009; 361(13): 1230–1233.
7.
GarberA.M.TunisS.R.. Does comparative-effectiveness research threaten personalized medicine? N Engl J Med.May 72009; 360(19): 1925–1927.
8.
American Academy of Dermatology Work G, Menter A, Korman NJ, et al.Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.J Am Acad Dermatol. Jul 2011; 65(1): 137–174.
9.
AuS.C.MadaniA.AlhaddadM.AlkofideM.GottliebA.B.. Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center.J Drugs Dermatol. Aug 2013; 12(8): 861–866.
10.
KriegerN.ChenJ.T.WatermanP.D.Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter?: the Public Health Disparities Geocoding Project. Am J Epidemiol.Sep 12002; 156(5): 471–482.
11.
LevinA.A.GottliebA.B.AuS.C.. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies.J Drugs Dermatol. Jul 2014; 13(7): 848–853.
12.
DommaschE.WoodcockJ.ShinD.DuffinK.GelfandJ.. Validity of the Simple-Measure for Assessing Psoriasis Activity (S-MAPA).World Congress Dermatology; Seoul, Korea. 2011.
13.
WalshJ.A.McFaddenM.WoodcockJ.Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort.J Am Acad Dermatol. Dec 2013; 69(6): 931–937.
14.
ArmstrongA.W.BagelJ.Van VoorheesA.S.RobertsonA.D.YamauchiP.S.. Combining Biologic Therapies With Other Systemic Treatments in Psoriasis: Evidence-Based, Best-Practice Recommendations From the Medical Board of the National Psoriasis Foundation.JAMA Dermatol.
15.
LyndeC.W.GuptaA.K.GuentherL.A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept.J Dermatolog Treat. Aug 2012; 23(4): 261–267.
16.
ParkK.K.WuJ.J.KooJ.. A randomized, ‘head-to-head’ pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients.J Eur Acad Dermatol Venereol. Jul 2013; 27(7): 899–906.
17.
GottliebA.B.LangleyR.G.StroberB.E.A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plague psoriasis.Br J Dermatol. Sep 2012; 167(3): 649–657.
18.
ZachariaeC.MorkN.J.ReunalaT.The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inade guate effect of methotrexate therapy.Acta Derm Venereol.2008; 88(5): 495–501.
19.
PuzenatE.BronsardV.PreyS.What are the best outcome measures for assessing plague psoriasis seventy? A systematic review of the literature.J Eur Acad Dermatol Venereol. Apr 2010; 24 Suppl 2: 10–16.
20.
SpulsP.I.LecluseL.L.PoulsenM.L.How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review.J Invest Dermatol. Apr 2010; 130(4): 933–943.
